Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
San-Huang Gu-Ben Zhi-Ke (SHGBZK) is a Traditional Chinese Medicine (TCM) herbal formula developed by Beijing Hospital for the treatment of stable chronic obstructive pulmonary disease (COPD). It is specifically indicated for patients presenting with the lung-spleen Qi deficiency syndrome. The formula typically contains herbs such as Astragalus membranaceus (Huangqi), Scutellaria baicalensis (Huangqin), and Polygonum cuspidatum (Huzhang), which collectively represent the 'San-Huang' (Three Yellows) components. SHGBZK is designed to 'consolidate the root' (Gu-Ben), referring to strengthening the body's vital energy, and 'relieve cough' (Zhi-Ke). Clinical studies have demonstrated that SHGBZK can significantly improve respiratory symptoms, exercise capacity (as measured by the 6-minute walk test), and health-related quality of life. Evidence also suggests it may reduce the frequency of acute exacerbations and improve lung function in specific high-risk subgroups, such as patients with frequent exacerbations or high symptom burdens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on San-Huang Gu-Ben Zhi-Ke.